Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Leases (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Operating Leases data on record, last reported at $266000.0 in Q3 2025.

  • For Q3 2025, Operating Leases fell 62.0% year-over-year to $266000.0; the TTM value through Sep 2025 reached $266000.0, down 62.0%, while the annual FY2024 figure was $358000.0, 43.35% down from the prior year.
  • Operating Leases reached $266000.0 in Q3 2025 per TNXP's latest filing, down from $492000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $898000.0 in Q2 2023 and bottomed at $266000.0 in Q3 2025.
  • Average Operating Leases over 3 years is $584818.2, with a median of $528000.0 recorded in 2023.
  • Peak YoY movement for Operating Leases: surged 59.09% in 2024, then tumbled 62.0% in 2025.
  • A 3-year view of Operating Leases shows it stood at $632000.0 in 2023, then plummeted by 43.35% to $358000.0 in 2024, then fell by 25.7% to $266000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $266000.0 in Q3 2025, $492000.0 in Q2 2025, and $328000.0 in Q1 2025.